[Viva] Fwd: aidsmap news: News from IAS 2019, 12 August 2019

[Margarite Sanchez]

New studies out of the recent International AIDS Conference in Mexico City.
fyi

---------- Forwarded message ---------
From: aidsmap news <bulletins at bulletins.aidsmap.com>
Date: Mon, Aug 12, 2019 at 6:24 AM
Subject: aidsmap news: News from IAS 2019, 12 August 2019
To: <margaritesanchez at gmail.com>


Having problems reading this email? View it in your browser >>
<http://archive.aidsmap.com/page/3545604/>
[image: aidsmap news] <http://archive.aidsmap.com>


12 August 2019

<http://archive.aidsmap.com/donate>


News from IAS 2019
News from the International AIDS Society Conference on HIV Science
<http://www.aidsmap.com/conference/ias-2019?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

NAM was delighted to be selected as official provider of online science
news for the recent International AIDS Society Conference on HIV Science
(IAS 2019) in Mexico City. Catch up on the news headlines below, or visit
our conference webpages for all our reporting.

Read more >>
<http://www.aidsmap.com/conference/ias-2019?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
High and increasing HIV incidence in young Latin American gay men
<https://www.aidsmap.com/news/aug-2019/high-and-increasing-hiv-incidence-young-latin-american-gay-men?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

In Latin America, 40% of new HIV infections are in men who have sex with
men (MSM) and the recent International AIDS Society Conference on HIV
Science (IAS 2019) in Mexico City was the appropriate venue for the first
data from the largest ever survey of the region’s MSM to be released.

Read more >>
<https://www.aidsmap.com/news/aug-2019/high-and-increasing-hiv-incidence-young-latin-american-gay-men?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Cash payments to stay in school reduce HIV incidence in girls and young
women, eSwatini study finds
<https://www.aidsmap.com/news/aug-2019/cash-payments-stay-school-reduce-hiv-incidence-girls-and-young-women-eswatini-study?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Financial incentives to remain in school reduced HIV incidence among
adolescent girls and young women in eSwatini (Swaziland) by 21%, and
participants exposed to both financial incentives and a lottery open only
to those who remained free of sexually transmitted infections were 37% less
likely to acquire HIV infection, a trial has found.

Read more >>
<https://www.aidsmap.com/news/aug-2019/cash-payments-stay-school-reduce-hiv-incidence-girls-and-young-women-eswatini-study?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Punitive laws associated with HIV infections in female sex workers
<https://www.aidsmap.com/news/aug-2019/punitive-laws-associated-hiv-infections-female-sex-workers?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The presence of laws criminalising sex work is associated with a sevenfold
increase in the odds of HIV infection among female sex workers in
sub-Saharan Africa, according to research presented to IAS 2019. In
settings where sex work was criminalised, female sex workers were also more
likely to experience violence and stigma in social and healthcare settings.
The research was conducted in ten countries with different approaches to
the criminalisation of sex work, and the investigators conclude that
criminalisation and stigma are helping drive the HIV epidemic among sex
workers.

Read more >>
<https://www.aidsmap.com/news/aug-2019/punitive-laws-associated-hiv-infections-female-sex-workers?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Leakages in ART treatment cascades in West Africa and Zambia
<https://www.aidsmap.com/news/aug-2019/leakages-art-treatment-cascades-west-africa-and-zambia?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Two studies presented at IAS 2019 showed significant leakages in the
antiretroviral therapy (ART) treatment cascade. A study of eleven West and
Central African countries showed low numbers of viral load tests conducted
as well as stock-outs of HIV tests, ART and viral load testing supplies.
Another study looked at the cascade of virologically unsuppressed people
living with HIV in Zambia and found gaps and substantial delays with
provision of follow-up viral load testing.

Read more >>
<https://www.aidsmap.com/news/aug-2019/leakages-art-treatment-cascades-west-africa-and-zambia?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Dramatic decline in proportion of people with extensive resistance to
anti-HIV medications
<https://www.aidsmap.com/news/aug-2019/dramatic-decline-proportion-people-extensive-resistance-anti-hiv-medications?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The proportion of people in the United States with extensive resistance to
antiretroviral therapy (ART) and limited treatment options declined
markedly after 2012, in large part thanks to the availability of potent new
drugs, according to research presented to IAS 2019. Since 2012, only 1% of
people who have taken ART have had extensive resistance.

Read more >>
<https://www.aidsmap.com/news/aug-2019/dramatic-decline-proportion-people-extensive-resistance-anti-hiv-medications?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Young adults with vertical HIV and hepatitis C co-infection have a high
hepatitis C cure rate
<https://www.aidsmap.com/news/aug-2019/young-adults-vertical-hiv-and-hepatitis-c-co-infection-have-high-hepatitis-c-cure?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Young adults with vertically transmitted HIV and hepatitis C virus (HCV)
co-infection can easily be cured with direct-acting antivirals (DAAs), but
some already have advanced liver damage by the time they are treated,
researchers reported at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/aug-2019/young-adults-vertical-hiv-and-hepatitis-c-co-infection-have-high-hepatitis-c-cure?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
13% of HIV-positive Europeans who are cured of hepatitis C are reinfected
<https://www.aidsmap.com/news/jul-2019/13-hiv-positive-europeans-who-are-cured-hepatitis-c-are-reinfected?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

More than one in ten HIV-positive people in the large EuroSIDA cohort who
were cured of hepatitis C were reinfected within two years, according to a
report at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/13-hiv-positive-europeans-who-are-cured-hepatitis-c-are-reinfected?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Could a better understanding of inflammation help research towards an HIV
cure?
<https://www.aidsmap.com/news/jul-2019/could-better-understanding-inflammation-help-research-towards-hiv-cure?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Michaela Müller-Trutwin of the Institut Pasteur in Paris gave an overview
of research on immune activation and HIV-induced inflammation at IAS 2019.
She highlighted the links between chronic inflammation and the
establishment of the HIV reservoir. She also shared insights from non-human
primates which escape inflammation despite high viraemia, suggesting a
crucial role for natural killer cells.

Read more >>
<https://www.aidsmap.com/news/jul-2019/could-better-understanding-inflammation-help-research-towards-hiv-cure?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Same-day initiation of PrEP feasible and safe in Latin America
<https://www.aidsmap.com/news/jul-2019/same-day-initiation-prep-feasible-and-safe-latin-america?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Over 5000 men who have sex with men and transgender women have been
enrolled in the ImPrEP demonstration project in Brazil, Mexico and Peru,
with early results showing good levels of adherence and continuation, IAS
2019 heard. This was one of several studies reporting on efforts to
scale-up pre-exposure prophylaxis (PrEP) in Latin America presented at the
conference.

Read more >>
<https://www.aidsmap.com/news/jul-2019/same-day-initiation-prep-feasible-and-safe-latin-america?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Without frequent viral load monitoring dolutegravir-based regimens not the
best choice for African youth on failing ART
<https://www.aidsmap.com/news/jul-2019/without-frequent-viral-load-monitoring-dolutegravir-based-regimens-not-best-choice?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

A high proportion of adolescents and young adults living with HIV in
Zimbabwe on failing first-line non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based regimens had clinically significant resistance
mutations which could compromise the efficacy of a new regimen of
tenofovir, lamivudine and dolutegravir, IAS 2019 heard.

Read more >>
<https://www.aidsmap.com/news/jul-2019/without-frequent-viral-load-monitoring-dolutegravir-based-regimens-not-best-choice?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
HIV outcomes for transgender women improved by addressing social and
structural issues
<https://www.aidsmap.com/news/jul-2019/hiv-outcomes-transgender-women-improved-addressing-social-and-structural-issues?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

An integrated healthcare model providing screening, referral and service
provision for transgender women of colour boosted rates of engagement with
the HIV care continuum over 24 months, according to research presented to
IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/hiv-outcomes-transgender-women-improved-addressing-social-and-structural-issues?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
'Mystery shoppers' in Kenyan pharmacies highlight issues with distribution
of HIV self-tests
<https://www.aidsmap.com/news/jul-2019/mystery-shoppers-kenyan-pharmacies-highlight-issues-distribution-hiv-self-tests?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Private sector providers may need more support and training to effectively
distribute HIV self-testing kits to adolescents and young adults, according
to research conducted in Kenya and presented to IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/mystery-shoppers-kenyan-pharmacies-highlight-issues-distribution-hiv-self-tests?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Fostemsavir salvage therapy continues to look good at 96 weeks
<https://www.aidsmap.com/news/jul-2019/fostemsavir-salvage-therapy-continues-look-good-96-weeks?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The novel HIV attachment inhibitor fostemsavir continues to maintain viral
suppression in more than half of people with extensive prior treatment
experience and highly resistant virus, according to a report at IAS 2019.
Study participants, many of whom had advanced immune suppression at
baseline, experienced substantial gains in CD4 cells.

Read more >>
<https://www.aidsmap.com/news/jul-2019/fostemsavir-salvage-therapy-continues-look-good-96-weeks?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Dolutegravir dual therapy works well for both first line and maintenance
treatment
<https://www.aidsmap.com/news/jul-2019/dolutegravir-dual-therapy-works-well-both-first-line-and-maintenance-treatment?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

A two-drug combination of dolutegravir and lamivudine – the drugs in the
*Dovato* co-formulation – continued to suppress viral load as well as a
standard three-drug regimen in people starting their initial HIV treatment.
The combination also maintained viral suppression in those who switched
from a standard regimen.

Read more >>
<https://www.aidsmap.com/news/jul-2019/dolutegravir-dual-therapy-works-well-both-first-line-and-maintenance-treatment?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Dapivirine vaginal ring effective and acceptable with longer use
<https://www.aidsmap.com/news/jul-2019/dapivirine-vaginal-ring-effective-and-acceptable-longer-use?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

A silicone vaginal ring containing the antiretroviral drug dapivirine
continued to demonstrate moderate effectiveness and remained well tolerated
and acceptable to African women over a year-long period, according to a
report presented at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/dapivirine-vaginal-ring-effective-and-acceptable-longer-use?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Does *Descovy* have a role as PrEP in people who struggle with adherence?
<https://www.aidsmap.com/news/jul-2019/does-descovy-have-role-prep-people-who-struggle-adherence?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

It’s possible that pre-exposure prophylaxis (PrEP) using tenofovir
alafenamide/emtricitacine (F/TAF, brand name *Descovy*) might have a role
in providing a more ‘forgiving’ PrEP regimen for people with sub-optimal
adherence to PrEP, or who take it intermittently, than the standard regimen
of tenofovir disoproxil fumarate (F/TDF, known by its brand name *Truvada*,
though increasingly available as a non-branded generic).

Read more >>
<https://www.aidsmap.com/news/jul-2019/does-descovy-have-role-prep-people-who-struggle-adherence?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Policing practices are consistently associated with HIV and risk behaviours
among people who inject drugs
<https://www.aidsmap.com/news/jul-2019/policing-practices-are-consistently-associated-hiv-and-risk-behaviours-among-people?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Being stopped, beaten or arrested by police, having syringes confiscated
and other policing practices are consistently associated with HIV infection
and risk behaviours among people who inject drugs in many settings, Pieter
Baker of the University of California San Diego told IAS 2019. Regular
interactions between the police and people who inject drugs affect how
people consume drugs and access HIV prevention programmes, he said.

Read more >>
<https://www.aidsmap.com/news/jul-2019/policing-practices-are-consistently-associated-hiv-and-risk-behaviours-among-people?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
First trial results of new immune-modulating drugs presented in Mexico City
<https://www.aidsmap.com/news/jul-2019/first-trial-results-new-immune-modulating-drugs-presented-mexico-city?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Several studies of new types of HIV drug that have previously only been in
pre-clinical (laboratory or animal) studies, or in drug level studies in
HIV-negative people, were presented at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/first-trial-results-new-immune-modulating-drugs-presented-mexico-city?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Could integrating HIV prevention into contraceptive services reduce
infections among African women?
<https://www.aidsmap.com/news/jul-2019/could-integrating-hiv-prevention-contraceptive-services-reduce-infections-among?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

ECHO, the landmark trial demonstrating that injectable hormonal
contraceptives do not raise women’s risk of acquiring HIV, released its
results just a month before IAS 2019. While providing reassuring news about
contraception, the study also revealed an unacceptably high incidence of
HIV among trial participants, despite the prevention services that had been
provided.

Read more >>
<https://www.aidsmap.com/news/jul-2019/could-integrating-hiv-prevention-contraceptive-services-reduce-infections-among?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Starting PrEP does not lead to more STIs, youth survey in Chicago finds
<https://www.aidsmap.com/news/jul-2019/starting-prep-does-not-lead-more-stis-youth-survey-chicago-finds?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

A survey of young gay and bisexual men and transgender women in Chicago, a
proportion of them taking pre-exposure prophylaxis (PrEP), has found no
direct relationship between starting PrEP and any increase in subsequent
sexually transmitted infections (STIs). It did find that, not unexpectedly,
people started having more condomless anal sex after starting PrEP, but
this did not translate into more STIs.

Read more >>
<https://www.aidsmap.com/news/jul-2019/starting-prep-does-not-lead-more-stis-youth-survey-chicago-finds?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Who stops taking PrEP, and why?
<https://www.aidsmap.com/news/jul-2019/who-stops-taking-prep-and-why?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Several studies presented at IAS 2019 looked at who discontinued HIV
pre-exposure prophylaxis (PrEP) after starting it as part of a
demonstration project.

Read more >>
<https://www.aidsmap.com/news/jul-2019/who-stops-taking-prep-and-why?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Islatravir plus doravirine may offer new dual therapy option
<https://www.aidsmap.com/news/jul-2019/islatravir-plus-doravirine-may-offer-new-dual-therapy-option?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Islatravir, the first nucleoside reverse transcriptase translocation
inhibitor, plus the recently approved non-nucleoside reverse transcriptase
inhibitor doravirine (*Pifeltro*) may offer a potent and well-tolerated
two-drug regimen for HIV maintenance therapy, according to a study
presented at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/islatravir-plus-doravirine-may-offer-new-dual-therapy-option?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Trial vaccine could protect against HIV for more than five years
<https://www.aidsmap.com/news/jul-2019/trial-vaccine-could-protect-against-hiv-more-five-years?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

New results from a phase IIa vaccine study, APPROACH, announced at IAS
2019, indicate that the antibody and cellular immune responses induced by
the vaccine last for at last two years, and that a protective antibody
response could last for at least five years, if it declines at a rate
typical of other vaccines.

Read more >>
<https://www.aidsmap.com/news/jul-2019/trial-vaccine-could-protect-against-hiv-more-five-years?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Four days on, three days off HIV treatment as effective as continuous
therapy, French study finds
<https://www.aidsmap.com/news/jul-2019/four-days-three-days-hiv-treatment-effective-continuous-therapy-french-study-finds?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Taking anti-HIV medication four days a week was as effective as daily
treatment for people who already had a fully suppressed viral load, early
data from a randomised trial presented at IAS 2019 suggest. The efficacy of
the approach, particularly in relation to resistance, will need to be
confirmed with longer follow-up than the 48-week data presented at the
conference.

Read more >>
<https://www.aidsmap.com/news/jul-2019/four-days-three-days-hiv-treatment-effective-continuous-therapy-french-study-finds?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
ADVANCE trial shows dolutegravir is highly effective in South Africa
<https://www.aidsmap.com/news/jul-2019/advance-trial-shows-dolutegravir-highly-effective-south-africa?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Dolutegravir-based treatment was just as effective as efavirenz-based
treatment in a large randomised trial in South Africa, and treatment with
the older and cheaper formulation of tenofovir was just as effective and
well tolerated as treatment with a newer formulation, according to results
of the ADVANCE study presented at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/advance-trial-shows-dolutegravir-highly-effective-south-africa?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Three forms of PrEP stigma in Kenya
<https://www.aidsmap.com/news/jul-2019/three-forms-prep-stigma-kenya?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Stigma remains a significant barrier to the uptake and continued use of
pre-exposure prophylaxis (PrEP) by key populations in Kenya, according to
qualitative research presented at IAS 2019 by Dr Daniel Were of the Jilinde
Project and Jhpiego.

Read more >>
<https://www.aidsmap.com/news/jul-2019/three-forms-prep-stigma-kenya?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
PrEP implant could last well over a year
<https://www.aidsmap.com/news/jul-2019/prep-implant-could-last-well-over-year?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Islatravir is the latest HIV drug name to be added to the ever-growing list
of antiretrovirals. The drug formerly known as MK-8591 was the subject of
one of the most keenly-awaited studies to be presented at IAS 2019. This
showed that an implant containing it, which is inserted under the skin of
the upper arm, should provide sustained levels of drug sufficient to
prevent HIV infection for over a year.

Read more >>
<https://www.aidsmap.com/news/jul-2019/prep-implant-could-last-well-over-year?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
WHO endorses event-driven PrEP for gay men
<https://www.aidsmap.com/news/jul-2019/who-endorses-event-driven-prep-gay-men?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The World Health Organization (WHO) has updated its recommendation for
pre-exposure prophylaxis (PrEP) to include event-driven PrEP taken before
and after sex – also called on-demand PrEP or the 2+1+1 schedule – as an
HIV prevention option for men who have sex with men.

Read more >>
<https://www.aidsmap.com/news/jul-2019/who-endorses-event-driven-prep-gay-men?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
South Africa saves $326 million on dolutegravir
<https://www.aidsmap.com/news/jul-2019/south-africa-saves-326-million-dolutegravir?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

South Africa’s public sector will save US$326 million over the next three
years as a result of competitive tendering exercise that pushed the price
of a fixed combination of tenofovir, lamivudine and dolutegravir down to
$65 a year. The savings will help South Africa to treat around 2 million
extra people, Herbert Musariri of the Clinton Health Access Initiative told
IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/south-africa-saves-326-million-dolutegravir?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Men accounted for two-thirds of HIV transmission in PopART prevention trial
<https://www.aidsmap.com/news/jul-2019/men-accounted-two-thirds-hiv-transmission-popart-prevention-trial?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Universal test and treat programmes need to prioritise reaching young
people to reduce HIV transmission, an analysis of the PopART HIV prevention
trial presented at IAS 2019 shows.

Read more >>
<https://www.aidsmap.com/news/jul-2019/men-accounted-two-thirds-hiv-transmission-popart-prevention-trial?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Dolutegravir leads to weight gain in two African studies
<https://www.aidsmap.com/news/jul-2019/dolutegravir-leads-weight-gain-two-african-studies?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Treatment with dolutegravir resulted in weight gain for participants in two
large clinical trials in sub-Saharan Africa and was especially pronounced
when dolutegravir was combined with the new formulation of tenofovir
(tenofovir alafenamide fumarate, TAF), Dr Michelle Moorhouse of Wits
Reproductive Health Institute, Johannesburg, reported at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/dolutegravir-leads-weight-gain-two-african-studies?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Home tests aren’t an accurate way for people on HIV treatment to check they
still have HIV
<https://www.aidsmap.com/news/jul-2019/home-tests-arent-accurate-way-people-hiv-treatment-check-they-still-have-hiv?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

HIV self-tests (home tests) frequently give false-negative results when
used by people with diagnosed HIV who are taking antiretroviral therapy,
with implications for the messaging around self-testing, according to a
South African study presented at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/home-tests-arent-accurate-way-people-hiv-treatment-check-they-still-have-hiv?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Low harm reduction coverage for people who inject drugs in South Africa
<https://www.aidsmap.com/news/jul-2019/low-harm-reduction-coverage-people-who-inject-drugs-south-africa?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The five most populated cities in South Africa (Cape Town, Durban,
Johannesburg, Pretoria and Port Elizabeth) have low coverage of harm
reduction services, Dr Andrew Scheibe of the non-profit organisation TB HIV
Care told IAS 2019. Needle and syringe services distributed an average of
76 needles per person using the service per year, ranging from 52 per
person in Pretoria to 174 in Cape Town.

Read more >>
<https://www.aidsmap.com/news/jul-2019/low-harm-reduction-coverage-people-who-inject-drugs-south-africa?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Statin therapy did not slow atherosclerosis progression in people with HIV
<https://www.aidsmap.com/news/jul-2019/statin-therapy-did-not-slow-atherosclerosis-progression-people-hiv?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

People with HIV who used the lipid-lowering medication rosuvastatin (
*Crestor*) to prevent progression of cardiovascular disease (CVD) saw no
reduction in progression of atherosclerosis, or 'hardening of the
arteries', despite the expected reduction in cholesterol, according to a
report at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/statin-therapy-did-not-slow-atherosclerosis-progression-people-hiv?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
People with HIV express high satisfaction with monthly injectable regimen
<https://www.aidsmap.com/news/jul-2019/people-hiv-express-high-satisfaction-monthly-injectable-regimen?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

People who received a combination of two long-acting injectable
antiretrovirals once a month expressed a high level of satisfaction with
the regimen and almost all said they preferred it to their previous oral
therapy, according to two studies presented at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/people-hiv-express-high-satisfaction-monthly-injectable-regimen?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Poorer HIV care outcomes for those using alcohol and drugs in sub-Saharan
African countries
<https://www.aidsmap.com/news/jul-2019/poorer-hiv-care-outcomes-those-using-alcohol-and-drugs-sub-saharan-african-countries?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

While it is well-established that alcohol and drug use lead to poorer
outcomes for those living with HIV in settings such as Europe and North
America, there is a scarcity of data for people living with HIV in
sub-Saharan Africa. Two studies presented at IAS 2019 showed poorer
engagement with HIV care for those drinking or using drugs.

Read more >>
<https://www.aidsmap.com/news/jul-2019/poorer-hiv-care-outcomes-those-using-alcohol-and-drugs-sub-saharan-african-countries?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Dolutegravir recommended for all in new World Health Organization guidelines
<https://www.aidsmap.com/news/jul-2019/dolutegravir-recommended-all-new-world-health-organization-guidelines?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Everyone who starts HIV treatment in lower- and middle-income countries
should start treatment with a combination containing dolutegravir, the
World Health Organization (WHO) announced at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/dolutegravir-recommended-all-new-world-health-organization-guidelines?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Dolutegravir safety in pregnancy: risk is lower than first reported
<https://www.aidsmap.com/news/jul-2019/dolutegravir-safety-pregnancy-risk-lower-first-reported?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Exposure to dolutegravir at the time of conception or during the first
three months of pregnancy is associated with a small increased risk of
neural tube defects, longer-term follow-up of a national birth cohort in
Botswana has found. The risk is lower than preliminary results suggested,
and the World Health Organization (WHO) has recommended that dolutegravir
should be available for all women.

Read more >>
<https://www.aidsmap.com/news/jul-2019/dolutegravir-safety-pregnancy-risk-lower-first-reported?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
UNAIDS outlines progress on HIV, but decries funding cuts
<https://www.aidsmap.com/news/jul-2019/unaids-outlines-progress-hiv-decries-funding-cuts?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The Joint United Nations Programme on HIV/AIDS (UNAIDS) released its latest
report on the status of the HIV epidemic and the global response ahead of
IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/unaids-outlines-progress-hiv-decries-funding-cuts?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Promising HIV vaccine to be tested with gay men and trans people
<https://www.aidsmap.com/news/jul-2019/promising-hiv-vaccine-be-tested-gay-men-and-trans-people?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

A new phase III HIV vaccine trial will soon be underway for men who have
sex with men and transgender people. The study, called Mosaico, will
evaluate a four-shot regimen of a vaccine designed to provide protection
against the many different strains of HIV around the world.

Read more >>
<https://www.aidsmap.com/news/jul-2019/promising-hiv-vaccine-be-tested-gay-men-and-trans-people?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
PrEP services could enhance STI control, says World Health Organization
<https://www.aidsmap.com/news/jul-2019/prep-services-could-enhance-sti-control-says-world-health-organization?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The roll-out of pre-exposure prophylaxis (PrEP) provides an opportunity to
bring down the incidence of sexually transmitted infections (STIs),
provided that PrEP and STI programmes are better co-ordinated and
integrated, representatives from the World Health Organization (WHO) said
at IAS 2019.

Read more >>
<https://www.aidsmap.com/news/jul-2019/prep-services-could-enhance-sti-control-says-world-health-organization?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Beyond antibodies: conference hears of new molecular tools to kill
HIV-infected reservoir cells
<https://www.aidsmap.com/news/jul-2019/beyond-antibodies-conference-hears-new-molecular-tools-kill-hiv-infected-reservoir?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The 2019 HIV and Hepatitis B Cure Forum took place on 20-21st July
immediately before IAS 2019 in Mexico City.

Read more >>
<https://www.aidsmap.com/news/jul-2019/beyond-antibodies-conference-hears-new-molecular-tools-kill-hiv-infected-reservoir?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Other recent news headlines
How can researchers reduce risks to sexual partners in studies involving
treatment interruptions?
<https://www.aidsmap.com/news/jul-2019/how-can-researchers-reduce-risks-sexual-partners-studies-involving-treatment?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

As studies working towards a functional cure or HIV eradication are
creating risks not only for the HIV-positive people who take part, but also
their sexual partners, researchers need to reconsider their ethical
obligations and the support they offer to non-participants, leading cure
researchers and ethicists argue in a supplement to the August 1 *Journal of
Infectious Diseases*.

Read more >>
<https://www.aidsmap.com/news/jul-2019/how-can-researchers-reduce-risks-sexual-partners-studies-involving-treatment?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Deportation fears, uncertainty over health insurance and stigma are
barriers to accessing HIV services for undocumented African migrants in the
US
<https://www.aidsmap.com/news/jul-2019/deportation-fears-uncertainty-over-health-insurance-and-stigma-are-barriers-accessing?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Qualitative research carried out with undocumented African migrants in New
York City revealed that fears of discovery and deportation presented a
substantial barrier to seeking out HIV testing services and treatment after
diagnosis. Migrants also expressed uncertainty regarding how to go about
obtaining health insurance and thought they were not eligible to access
health services.

Read more >>
<https://www.aidsmap.com/news/jul-2019/deportation-fears-uncertainty-over-health-insurance-and-stigma-are-barriers-accessing?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Hepatitis C does not raise risk of heart disease or cancers in people with
HIV
<https://www.aidsmap.com/news/jul-2019/hepatitis-c-does-not-raise-risk-heart-disease-or-cancers-people-hiv?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Hepatitis C co-infection does not increase the risk of cardiovascular
disease or non-AIDS cancers in people with HIV, an analysis of the large
Eurosida cohort published in *Clinical Infectious Diseases* has found.

Read more >>
<https://www.aidsmap.com/news/jul-2019/hepatitis-c-does-not-raise-risk-heart-disease-or-cancers-people-hiv?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Less than half of adolescents with HIV since birth in the US have an
undetectable viral load
<https://www.aidsmap.com/news/jul-2019/less-half-adolescents-hiv-birth-us-have-undetectable-viral-load?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Engagement with the HIV care continuum among individuals with
perinatally-acquired HIV in the United States falls well below targets,
research published in the online edition of the *Journal of Acquired Immune
Deficiency Syndromes* shows. Only three-quarters received any HIV care, 61%
were retained in care and 49% were virally suppressed. Those aged 18 to 25
years had especially low levels of engagement with the care continuum.

Read more >>
<https://www.aidsmap.com/news/jul-2019/less-half-adolescents-hiv-birth-us-have-undetectable-viral-load?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
What’s the relationship between PrEP, condom use and STIs?
<https://www.aidsmap.com/news/jul-2019/whats-relationship-between-prep-condom-use-and-stis?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

HIV experts and professionals agree that pre-exposure prophylaxis (PrEP) is
a valuable addition to HIV prevention, but have varied views of the
relationship between PrEP, reduced condom use and sexually transmitted
infections (STIs), according to a study published in *Sociology of Health &
Illness*.

Read more >>
<https://www.aidsmap.com/news/jul-2019/whats-relationship-between-prep-condom-use-and-stis?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Gay and bisexual men with problematic chemsex are a diverse group with
significant sexual and psycho-social risks
<https://www.aidsmap.com/news/jul-2019/gay-and-bisexual-men-problematic-chemsex-are-diverse-group-significant-sexual-and?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Men who have sex with men (MSM) seeking support because of chemsex are a
diverse group and have a range of behaviours that pose a high risk to their
physical health and psycho-social wellbeing, according to research
published in *Sexually Transmitted Infections*. Analysing the needs of gay
and bisexual men seeking support from Antidote (a specialist service
supporting LGBT individuals with drug and/or alcohol issues in London), the
study showed that MSM engaging in chemsex had a high prevalence of HIV
(47%), that many were current or past injectors and that thoughts of
suicide were common. But use of specific drugs and their associated health
outcomes differed according to several demographic factors, including age,
race and HIV infection status.

Read more >>
<https://www.aidsmap.com/news/jul-2019/gay-and-bisexual-men-problematic-chemsex-are-diverse-group-significant-sexual-and?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Australian gay and bisexual men interested in switching to on-demand PrEP
<https://www.aidsmap.com/news/jul-2019/australian-gay-and-bisexual-men-interested-switching-demand-prep?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

Half of gay and bisexual men using PrEP in Australia would be interested in
switching from taking daily PrEP to taking on-demand PrEP, and this
interest was most strongly associated with having sex infrequently and
concerns about long-term side-effects. The survey was carried out by Dr
Vincent Cornelisse and colleagues and is published in the July issue of *Open
Forum Infectious Diseases*.

Read more >>
<https://www.aidsmap.com/news/jul-2019/australian-gay-and-bisexual-men-interested-switching-demand-prep?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
Starting ART at a high CD4 cell count has clear benefits for people with a
low viral load
<http://aidsmap.com/news/jul-2019/starting-art-high-cd4-cell-count-has-clear-benefits-people-low-viral-load>

Starting antiretroviral therapy (ART) has significant benefits and entails
few risks for individuals with a low pre-treatment viral load, according to
analysis of results from a large treatment initiation study published in
the *Journal of Acquired Immune Deficiency Syndromes*. Prompt initiation of
ART was associated with robust increases in CD4 cell count, sustained viral
suppression and favourable changes in inflammatory biomarkers. The
investigators also calculated that treatment would have public health
benefits by almost eliminating the risk of onward HIV transmission.

Read more >>
<http://aidsmap.com/news/jul-2019/starting-art-high-cd4-cell-count-has-clear-benefits-people-low-viral-load>
Editors' picks from other sources
How voluntary licensing agreements are transforming HIV care
<https://www.devex.com/news/how-voluntary-licensing-agreements-are-transforming-hiv-care-95362>

from Devex

The rapid timeline for access to WHO-recommended dolutegravir is
unprecedented.
The promise and challenge of stem cell transplants in HIV cure
<http://hivcure.com.au/2019/08/08/stem-cell-transplants-hiv-cure/>

from HIV Cure

Stem cell transplantation will never be the basis for a widespread HIV
cure. However, careful study of people living with HIV who need stem cell
transplantation can lead to better understanding of HIV persistence and
conditions for elimination.
IAS 2019: Data shows indigenous, nonbinary populations among those missed
by HIV epidemic ending efforts
<https://sciencespeaksblog.org/2019/07/23/ias-2019-data-shows-indigenous-nonbinary-populations-among-those-missed-by-hiv-epidemic-ending-efforts/>

from Science Speaks

Indigenous communities in the Americas are largely being left out of
efforts to achieve UNAIDS’ 90-90-90 targets.
Would you want a computer to judge your risk of HIV infection?
<https://www.nytimes.com/2019/07/30/health/hiv-aids-prep.html>

from New York Times

A new software algorithm decides which patients are most likely to become
infected with the virus. Does the assessment stigmatize patients?

News from IAS 2019
<http://www.aidsmap.com/conference/ias-2019?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
<http://www.aidsmap.com/conference/ias-2019?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

The 10th International AIDS Society Conference on HIV Science (IAS 2019)
was held in Mexico City from 21 to 24 July 2019.

Visit our conference webpages for all our news reporting >>
<http://www.aidsmap.com/conference/ias-2019?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
aidsmapLIVE on HIV & mental health <https://www.facebook.com/aidsmap>

Join us on Tuesday 20th August for aidsmapLIVE: our live panel discussion
on HIV and mental health.

We’re thrilled to announce our panellists: Bakita Kasadha, Alex
Causton-Ronaldson, Dr Tristan Barber, Dr Rageshri Dhairywan and Dr John
Forni. Our panellists will share their knowledge on issues around HIV and
mental health and take your questions live.

Tune in on Tuesday 20th August at 6pm BST at: facebook.com/aidsmap
<https://www.facebook.com/aidsmap>
Work Positive
<https://www.tht.org.uk/our-work/community-projects/work-positive>
<https://www.tht.org.uk/our-work/community-projects/work-positive>

Are you living with HIV in the UK and unemployed? Would you like to gain
skills and confidence? Do you want to get back into the workplace?

The Terrence Higgins Trust Work Positive programme is now open for
applications.

To find out more or to apply for a place, email workpositive at tht.org.uk.

Applications close 12 August.

www.tht.org.uk/workpositive
<https://l.facebook.com/l.php?u=https%3A%2F%2Fwww.tht.org.uk%2Fworkpositive%3Ffbclid%3DIwAR34WiOVogzE1IjA5nEPppRlG6jZhm2tsF8iQWKHLyaGOvL9fZkoLjUK5Ww&h=AT0yHvV8NThUVYMGGVtlcbxuTgH2S7vjnEoIIYYOB9LVrMkI9yNp8ufOln222L3-3Rxv9YSKNlznJ4yiD4lJ7xolqXNw72r37wJjr7mXr81Qazs_wPcQS3GCfWSY2sTtBGktdgZm0n2pOwkx7bKCBX2m3HDvOD_F7945KzGboS3p2pr3mRn3xxXsyAJGcVoO9nTWCEmk8L7hT8HGetMl4StqGLNWsIK6xVVQDPmuMBn0qmEhFlDGlhl1fuZTYwbxPvlyYxDIYqi-EyEEQrFf5qNy1-dhxMR2k_6TNc7BKhZ8S9Ulm6uxWzf81hAIJKYBw8S8evWLlnYwuPe6O-Jh4crPS6BrWbXYpghdBXfXqLw-LuC2sXuPpgtmOflmSYDBKAaaFznQ3EqF5mdwuR1k1GG7Q7ZkYht9u1tYpFCzzRkcCjqDNlTw1NPqBI4b6m5rr3QBys8dDKNnIfHFJHjCVWotEkZGyFu7D94tMq4JOND7h7WJwCEg8sXEmsr5lWw0mQOjn-Rb7AlvnrHZo9EuYek7qkn8OSPehD2FCPsocgCkVAkxFhnkrKxowv_bF_TQ4fraUysWiRaECykK3-DQU2bNXfl84TUymRPDQzCBpG22kNG5IEmYWT_Ynbx0OQj4>
The fight for access to abortion care in Europe
<http://archive.aidsmap.com/page/3537973/>
<http://archive.aidsmap.com/page/3537973/>

Access to sexual and reproductive health and rights includes safe and legal
abortion care but, for many women in Europe, significant barriers remain.

We spoke to Caroline Hickson, Regional Director of the International
Planned Parenthood Federation European Network (IPPF EN), about access to
abortion across the region and IPPF EN’s advocacy work.

Read the e-feature interview >>
<http://www.aidsmap.com/page/3537973/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
New factsheet: The search for an HIV cure
<http://archive.aidsmap.com/page/3535629/>
<http://archive.aidsmap.com/page/3535629/>

There has been a lot of excitement around the second person reported to be
'cured' of HIV, but what does it mean for other people living with HIV? How
close are we to finding a cure?

Read our new factsheet to find out about potential strategies towards a
cure; reported cases of HIV cure and remission; and possible risks for
participants in cure research trials.

Read *The search for an HIV cure* >>
<http://archive.aidsmap.com/page/3535629/>




NAM is an award-winning, community-based organisation, which works from the
UK. We deliver reliable and accurate HIV information across the world to
HIV-positive people and to the professionals who treat, support and care
for them.

Make a donation, make a difference at www.aidsmap.com/donate
<http://www.aidsmap.com/donate?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

*For more details, please contact NAM*
tel: +44 (0)20 7837 6988
fax: +44 (0)20 7923 5949
email: info at nam.org.uk
web: www.aidsmap.com
<http://www.aidsmap.com/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

*NAM Publications*
Registered office: Acorn House, 314-320 Gray’s Inn Road, London, WC1X 8DP
Company limited by guarantee. Registered in England & Wales, number: 2707596
Registered charity, number: 1011220

*Privacy Policy*
Read it here: http://www.aidsmap.com/page/1439297/
<http://www.aidsmap.com/page/1439297/?utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>

To unsubscribe please visit: http://www.aidsmap.com/page/1492854/
<http://www.aidsmap.com/page/1492854/?type=x&utm_source=NAM-Email-Promotion&utm_medium=aidsmap-news&utm_campaign=aidsmap-news>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20190812/77a6d975/attachment-0001.html>